Extended Methods: Mendelian Randomization
Mendelian randomization is one of the methods that can be used to test causal relationship between risk factors and various phenotypes including disease outcomes using genetic variation as a natural experiment. Growing number of SNPs that are convincingly associated with certain risk factors (e.g. smoking habits, blood lipid profile or presence of periodontitis) in GWAS allows researchers to use these SNPs as instrumental variables that approximate lifetime exposure to risk factor and test these SNPs for an association with a phenotype of interest. There are three key assumptions that MR analysis must meet to be valid:1.
Relevance -selected SNPs associate with the risk factor, 2-Independence -lack of unmeasured confounders of the association between SNP and the outcome 3. Exclusion restriction-SNPs affect the outcome exclusively via their effect on selected risk factor 1 .
Several statistical tests were developed in order to provide valid estimates of MR analysis.
Inverse variance weighted method provides unbiased results when the 3 rd assumption is met i.e. no horizontal pleiotropic variants are included in the analysis. Horizontal pleiotropy occurs when a genetic variant affects hypertension both through periodontitis and mechanisms other than periodontitis. Since it is often difficult to ensure lack of horizontal pleiotropic variants in the study, other methods are often used. For example, median-based methods proved valid estimates when at least half of the tested variants have no pleiotropic effects 1 
.
A recently developed Mendelian randomization pleiotropy residual sum and outlier (MR-PRESSO) test aims to identify pleiotropic variants in order to correct results of MR analysis accordingly 2 .
A two-sample mendelian randomization (MR) analysis was performed to investigate a causal link between periodontitis and blood pressure. Four SNPs, in LOC107984137 (rs729876), MTND1P5 (rs16870060), DEFA1A3 (rs2738058) and SIGLEC5 (rs4284742) loci, previously associated (with p value <5x10 -8 ) with periodontitis in GWAS 3, 4 , were used as instrumental variables (IVs) in Mendelian Randomization analysis. These SNPs, were then used as a periodontitis' exposure proxy, which were then tested in the context of blood pressure phenotypes. A palindromic rs1537415 SNP in GLT6D1, associated with periodontitis in GWAS as well 5 , was excluded from the analysis due to high allele frequency as well as due to the lack of proxy SNPs in Caucasians. For rs1537415 strand and allele alignment were deemed unreliable between different studies (i.e. original GWAS for periodontitis and ICBP+UK Biobank GWAS for blood pressure traits).
GWAS data on blood pressure, performed by Evangelou et al. 6 from UK-Biobank and ICBP-GWAS (including ~750,000 participants), were used to extract estimates of association between IVs and systolic, diastolic blood pressure (SBP, DBP) and pulse pressure (PP). As indicated in the original studies, off-treatment blood pressure values for treated individuals were imputed by adding 15mmHg to measured SBP and 10mmHg to measured DBP for all treated individuals. 6, 7 
Randomized Clinical Trial
We performed a single-center, parallel-group, randomized study to assess the effect of intensive non-surgical periodontal therapy (IPT; whole mouth subgingival and supragingival scaling of the teeth using also 0.2% chlorhexidine gel) compared with conventional care (supragingival scaling) and a 2 months follow-up. Consecutive patients from general dental practices in Krakow, Poland and from among referrals to the University Dental Clinic in Krakow. Patients who had previously been diagnosed with hypertension (in accordance with ESC/ESH diagnostic criteria 8 , were receiving stable treatment using at least 1 antihypertensive agent, since at least 6 months, and had an office blood pressure of >140/90 mmHg at the time of visit (average of at least 3 resting measurements) 9 were enrolled into the study if they also presented with moderate to severe periodontitis (using the CDC-AAP case definitions) 10, 11 . In brief, moderate periodontitis was defined as ≥2 interproximal sites with AL ≥4 mm (not on same tooth), or ≥2 interproximal sites with PD ≥5 mm (not on same tooth)and severe periodontitis as≥2 interproximal sites with AL ≥6 mm (not on same tooth) and ≥1 interproximal site with PD ≥5 mm Exclusion criteria included acute and major chronic inflammatory/immune disorders including autoimmune conditions, infections (including tuberculosis, HIV, hepatitis B and C), pulmonary, liver diseases and malignancies (within the last 5 years) and assessed by the examining clinician. Patients who had received treatment with medications known to affect periodontal status were also excluded (phenytoin and ciclosporin). Patient with furcation involvement were also excluded. Patients using any form of systemic or local immunosuppression (including steroids) within the previous 6 months were excluded, as were patients with any cause of secondary hypertension.
After identification in general medical practice all eligible participants were first screened for office blood pressure as well as full dental examination for inclusion into the study. Secondly, the 1 st study visit (baseline) occurred within 3-14 days from the patient identification visit. At baseline, ambulatory 24h blood pressure monitoring (ABPM), blood samples collection and vascular function assessment were undertaken. ABPM was removed 24 hours later in all participants, during the first dental treatment session. All patients who fulfilled criteria and provided informed consent were randomized, after run-in period, 1:1 using a computergenerated table to receive either IPT or CPT. Treatment allocation was concealed in an opaque envelope that was opened on the day of treatment by the treating physician. All other investigators, including cardiovascular physicians, blood pressure nurses, laboratory staff as well as staff involved in data collection and analysis remained masked to the treatment allocation.
IPT consisted of a single session of whole mouth supragingival and subgingival scaling of the teeth under local anesthesia with the topical application of 0.2% chlorhexidine gel (PerioKin; UK). CPT consisted of a single session of supragingival scaling of the teeth. All participants received dental hygiene instructions and were then followed up the next day, 7-10 days later and 2 months after the dental treatment session. Full dental examination and cardiovascular assessments were repeated 2 months after therapy. At the end of the study patients with CPT received subgingival dental scaling as required. None of the patients in the study required additional session of dental treatment during the study. Patient's report of their drug adherence was recorded during each visit. Patients were asked to bring their medications to each visit and were carefully interviewed regarding adherence. Patient anti-hypertensive medications were provided as standard of care. Any change of medication/dosage resulted in exclusion from the study and this happened in 2 patients (4%) in intensive group and 3 patients (5.8%) in conventional therapy group in patients who were subsequently lost to follow-up. In summary, no difference in adherence was observed using this approach.
Average 24h ambulatory blood pressure at 2 months was the prespecified primary outcome, while vascular function and inflammatory soluble and cellular biomarkers were secondary endpoints. The study was approved by the Jagiellonian University Ethics Committee. All participants provided written informed consent prior to being enrolled into the study The study was registered with ClinicalTrials.gov -NCT02131922
Office and 24h ABPM determination
Office blood pressure was measured using Omron M digital blood pressure monitor by a blood pressure clinic nurse. Three measurements after resting in a quiet and temperaturecontrolled room were performed and average was recorded. ABPM was performed using Spacelabs Ultralite 90217 devices in accordance with manufacturer recommendations and in agreement with current ESC/ESH Guidelines. 9 
Vascular Function Assessment
Flow-mediated dilatation (FMD) of the brachial artery was used to determine the vascular endothelial function and NMD (nitroglycerine-mediated dilatation) was used for measuring endothelial-independent vasodilatation. Analysis was performed analyzed using Vascular Tools 5 software by 2 independent vascular technicians masked to the treatment allocation and as previously described. 12, 13 Flow cytometric analysis cells. In T cells and their subsets, the expressions of surface activation markers were then assessed. Monocytes were gated according to forward scatter (FSC) and side scatter (SSC) signals as described previously 12, 14, 15 . Subsequently, cells were gated in an HLA-DR/CD14 plot to exclude HLA-DR-negative Natural Killer cells. Finally, monocyte subsets were defined according to the CD14 and CD16 expression, which allowed for discrimination of major monocyte subpopulations: CD14++CD16−, CD14++CD16+ and CD14+CD16++. Fluorescence 
Statistical analysis
Analyses were performed with SPSS (ver. 25.0) statistical package, unless otherwise stated.
MR analysis was performed using MR-PRESSO (Mendelian Randomization Pleiotropy RESidual
Sum and Outlier) 2 . Additional causal estimation analyses were performed using inverse variance-weighted (IVW), and simple median-based methods using MendelianRandomization package in R (ver. 3.5.1). 18 Based on previous evidence, the clinical study was powered (80%) with a sample of 50 participants per group to detect a 7 mmHg difference in blood pressure between study groups and a 13 mmHg standard deviation of the change in systolic blood pressure [19] [20] [21] [22] . All the analyses were performed on the basis of the intention-to-treat principle, per protocol analyses for the outcomes reported are included. Means and 95% confidence intervals (95% C.I.)of continuous variables are presented according to treatment groups. Categorical variables counts and percentages are presented according to the treatment group and values were tested using chi-square test. In the discovery analyses cytokines and cell types were compared using paired t test for each of the treatment groups separately. Between group differences and differences from baseline to two-months follow up were tested with the use of repeated measures ANOVA with interaction term between group and time defined by 2 visits. We used one sided tests for analysis of cytokines and cell types based on hypothesis from previous studies 19 . Correlation analyses between the blood pressure outcomes and changes in dental parameters were performed using Spearman Rank tests.
Mediation analysis was performed using mediation package in R 23, 24 and tested average causal mediation effect of treatment group on change in SBP that is due to the change in PPD. P values < 0.05 were considered significant. 
